<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696731</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-316-101</org_study_id>
    <nct_id>NCT04696731</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma</brief_title>
  <acronym>TRAVERSE</acronym>
  <official_title>A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allogene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allogene Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the&#xD;
      TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults&#xD;
      with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen&#xD;
      comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-316</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-316</measure>
    <time_frame>33 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced/Metastatic Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>ALLO-647, ALLO-316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ALLO-316</intervention_name>
    <description>ALLO-316 is an allogeneic CAR T cell therapy targeting CD70</description>
    <arm_group_label>ALLO-647, ALLO-316</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-647</intervention_name>
    <description>ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen</description>
    <arm_group_label>ALLO-647, ALLO-316</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-647, ALLO-316</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-647, ALLO-316</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma with a predominant clear cell component.&#xD;
&#xD;
          -  Must have received a checkpoint inhibitor and a VEGF inhibitor in the advanced and/or&#xD;
             metastatic setting.&#xD;
&#xD;
          -  At least one measurable lesion as defined by RECIST version 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.&#xD;
&#xD;
          -  Absence of donor (product)-specific anti-HLA antibodies (DSA).&#xD;
&#xD;
          -  Adequate hematological, renal, liver, pulmonary, and cardiac functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system (CNS) metastatic disease (unless controlled and stable for at&#xD;
             least 4 weeks), leptomeningeal disease, or cord compression.&#xD;
&#xD;
          -  Clinically significant CNS dysfunction.&#xD;
&#xD;
          -  Any other active malignancy within 3 years prior to enrollment.&#xD;
&#xD;
          -  Prior treatment with anti-CD70 therapies.&#xD;
&#xD;
          -  Current thyroid disorder (including hyperthyroidism) with the exception of&#xD;
             hypothyroidism controlled on stable dose of hormone replacement therapy.&#xD;
&#xD;
          -  Prior treatment with anti-CD52 monoclonal antibody in the past 12 months.&#xD;
&#xD;
          -  Patients unwilling to participate in the extended safety monitoring period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Allogeneic Cell Therapy</keyword>
  <keyword>Cellular Immuno-therapy</keyword>
  <keyword>AlloCAR T</keyword>
  <keyword>ALLO-316</keyword>
  <keyword>ALLO-647</keyword>
  <keyword>CCRCC</keyword>
  <keyword>Clear Cell Renal Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

